Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 221.4 SEK 4.04% Market Closed
Market Cap: 30B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Vitrolife AB
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vitrolife AB
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Vitrolife AB
STO:VITR
Other Current Liabilities
kr192m
CAGR 3-Years
48%
CAGR 5-Years
27%
CAGR 10-Years
9%
Biogaia AB
STO:BIOG B
Other Current Liabilities
kr51.3m
CAGR 3-Years
19%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Other Current Liabilities
kr91.1m
CAGR 3-Years
42%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Probi AB
STO:PROB
Other Current Liabilities
kr35.4m
CAGR 3-Years
8%
CAGR 5-Years
-5%
CAGR 10-Years
5%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Other Current Liabilities
kr6.4B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
24%
BioArctic AB
STO:BIOA B
Other Current Liabilities
kr49.3m
CAGR 3-Years
-17%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
No Stocks Found

Vitrolife AB
Glance View

Market Cap
30B SEK
Industry
Biotechnology

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

VITR Intrinsic Value
139.61 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Vitrolife AB's Other Current Liabilities?
Other Current Liabilities
192m SEK

Based on the financial report for Sep 30, 2024, Vitrolife AB's Other Current Liabilities amounts to 192m SEK.

What is Vitrolife AB's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
9%

Over the last year, the Other Current Liabilities growth was 54%. The average annual Other Current Liabilities growth rates for Vitrolife AB have been 48% over the past three years , 27% over the past five years , and 9% over the past ten years .

Back to Top